The role of metabotropic glutamate receptors in Alzheimer's disease

Acta Neurobiologiae Experimentalis

Volumn 64, Issue 1, 2004, Pages 89-98

  Lee, Hyoung Gon ^a   Zhu, Xiongwei ^a   O'Neill, Michael J ^b   Webber, Kate ^a   Casadesus, Gemma ^a   Marlatt, Michael ^a   Raina, Arun K ^a   Perry, George ^a   Smith, Mark A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Alzheimer's disease; Glutamate receptor; Selective neurodegeneration

Indexed keywords

METABOTROPIC RECEPTOR;

ALZHEIMER DISEASE; GLUTAMATERGIC TRANSMISSION; HIPPOCAMPUS; HUMAN; NERVE DEGENERATION; NERVE PROJECTION; NEUROTRANSMISSION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN LOCALIZATION; REVIEW;

ALZHEIMER DISEASE; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 1842607573     PISSN: 00651400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Allen JW, Ivanova SA, Fan L, Espey MG, Basile AS, Faden AI (1999) Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury. J Pharmacol Exp Ther 290: 112-120.
2. Armstrong DM, Ikonomovic MD, Sheffield R, Wenthold RJ (1994) AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer's disease. Brain Res 639: 207-216.
3. Aronica E, Dickson DW, Kress Y, Morrison JH, Zukin RS (1998) Non-plaque dystrophic dendrites in Alzheimer hippocampus: a new pathological structure revealed by glutamate receptor immunocytochemistry. Neuroscience 82: 979-991.
4. Aronica E, Catania MV, Geurts J, Yankaya B, Troost D (2001) Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes. Neuroscience 105: 509-520.
5. Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, Leenstra S, Troost D (2003) Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci 17: 2106-2118.
6. Bao WL, Williams AJ, Faden AI, Tortella FC (2001) Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res 922: 173-179.
7. Battaglia G, Monn JA, Schoepp DD (1997) In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 229: 161-164.
8. Battaglia G, Bruno V, Pisani A, Centonze D, Catania MV, Calabresi P, Nicoletti F (2001) Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission. Mol Cell Neurosci 17: 1071-1083.
9. Bi H, Sze CI (2002) N-methyl-D-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer's disease. J Neurol Sci 200: 11-18.
10. Bond A, Jones NM, Hicks CA, Whiffin GM, Ward MA, O'Neill MF, Kingston AE, Monn JA, Ornstein PL, Schoepp DD, Lodge D, O'Neill MJ (2000) Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo. J Pharmacol Exp Ther 294: 800-809.
11. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
12. Bruno V, Battaglia G, Copani A, Giffard RG, Raciti G, Raffaele R, Shinozaki H, Nicoletti F (1995a) Activation of class II or III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. Eur J Neurosci 7: 1906-1913.
13. Bruno V, Copani A, Knopfel T, Kuhn R, Casabona G, Dell'Albani P, Condorelli DF, Nicoletti F (1995b) Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells. Neuropharmacology 34: 1089-1098.
14. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti F (1998) Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci 18: 9594-9600.
15. Bruno V, Battaglia G, Kingston A, O'Neill MJ, Catania MV, Di Grezia R, Nicoletti F (1999) Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology 38: 199-207.
16. Bruno V, Battaglia G, Ksiazek I, van der Putten H, Catania MV, Giuffrida R, Lukic S, Leonhardt T, Inderbitzin W, Gasparini F, Kuhn R, Hampson DR, Nicoletti F, Flor PJ (2000) Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J Neurosci 20: 6413-6420.
17. Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor PJ, Nicoletti F (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21: 1013-1033.
18. Buisson A, Choi DW (1995) The inhibitory mGluR agonist, S-4-carboxy-3-hydroxy-phenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death. Neuropharmacology 34: 1081-1087.
19. Buisson A, Yu SP, Choi DW (1996) DCG-IV selectively attenuates rapidly triggered NMDA-induced neurotoxicity in cortical neurons. Eur J Neurosci 8: 138-143.
20. Calabresi P, Centonze D, Pisani A, Bernardi G (1999) Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease. Exp Neurol 158: 97-108.
21. Cartmell J, Monn JA, Schoepp DD (2000) Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl) 148: 423-429.
22. Castellano C, Cestari V, Ciamei A (2001) NMDA receptors and learning and memory processes. Curr Drug Targets 2: 273-283.
23. Chalmers DT, Dewar D, Graham DI, Brooks DN, McCulloch J (1990) Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. Proc Natl Acad Sci U S A 87: 1352-1356.
24. Chiamulera C, Albertini P, Valerio E, Reggiani A (1992) Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischaemia. Eur J Pharmacol 216: 335-336.
25. Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13: 171-182.
26. Chuang SC, Bianchi R, Wong RK (2000) Group I mGluR activation turns on a voltage-gated inward current in hippocampal pyramidal cells. J Neurophysiol 83: 2844-2853.
27. Clayton DA, Mesches MH, Alvarez E, Bickford PC, Browning MD (2002) A hippocampal NR2B deficit can mimic age-related changes in long-term potentiation and spatial learning in the Fischer 344 rat. J Neurosci 22: 3628-3637.
28. Copani A, Bruno V, Battaglia G, Leanza G, Pellitteri R, Russo A, Stanzani S, Nicoletti F (1995) Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. Mol Pharmacol 47: 890-897.
29. Couratier P, Lesort M, Sindou P, Esclaire F, Yardin C, Hugon J (1996) Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol Chem Neuropathol 27: 259-273.
30. Croucher MJ, Patel H, Walsh DT, Moncaster JA, Gentleman SM, Fazal A, Jen LS (2003) Up-regulation of soluble amyloid precursor protein fragment secretion in the rat retina in vivo by metabotropic glutamate receptor stimulation. Neuroreport 14: 2271-2274.
31. Dewar D, Chalmers DT, Graham DI, McCulloch J (1991) Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: an autoradiographic study of the hippocampus. Brain Res 553: 58-64.
32. Esclaire F, Lesort M, Blanchard C, Hugon J (1997) Glutamate toxicity enhances tau gene expression in neuronal cultures. J Neurosci Res 49: 309-318.
33. Faden AI, Ivanova SA, Yakovlev AG, Mukhin AG (1997) Neuroprotective effects of group III mGluR in traumatic neuronal injury. J Neurotrauma 14: 885-895.
34. Ferraguti F, Baldani-Guerra B, Corsi M, Nakanishi S, Corti C (1999) Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors. Eur J Neurosci 11: 2073-2082.
35. Francis PT, Sims NR, Procter AW, Bowen DM (1993) Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem 60: 1589-1604.
36. Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, Fox M, Mattson MP (1996) Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 67: 1882-1896.
37. Gasparini F, Bruno V, Battaglia G, Lukic S, Leonhardt T, Inderbitzin W, Laurie D, Sommer B, Varney MA, Hess SD, Johnson EC, Kuhn R, Urwyler S, Sauer D, Portet C, Schmutz M, Nicoletti F, Flor PJ (1999) (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther 289: 1678-1687.
38. Geddes JW, Cotman CW (1986) Plasticity in hippocampal excitatory amino acid receptors in Alzheimer's disease. Neurosci Res 3: 672-678.
39. Geurts JJ, Wolswijk G, Bo L, van der Valk P, Polman CH, Troost D, Aronica E (2003) Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 126: 1755-1766.
40. Hyman BT, Van Hoesen GW, Damasio AR (1987) Alzheimer's disease: glutamate depletion in the hippocampal perforant pathway zone. Ann Neurol 22: 37-40.
41. Hynd MR, Scott HL, Dodd PR (2001) Glutamate(NMDA) receptor NR1 subunit mRNA expression in Alzheimer's disease. J Neurochem 78: 175-182.
42. Iacovelli L, Bruno V, Salvatore L, Melchiorri D, Gradini R, Caricasole A, Barletta E, De Blasi A, Nicoletti F (2002) Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways. J Neurochem 82: 216-223.
43. Ikonomovic MD, Sheffield R, Armstrong DM (1995) AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal formation of patients with Alzheimer's disease. Hippocampus 5: 469-486.
44. Ikonomovic MD, Mizukami K, Davies P, Hamilton R, Sheffield R, Armstrong DM (1997) The loss of GluR2(3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brains. J Neuropathol Exp Neurol 56: 1018-1027.
45. Ikonomovic MD, Mizukami K, Warde D, Sheffield R, Hamilton R, Wenthold RJ, Armstrong DM (1999) Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer's disease. Exp Neurol 160: 194-204.
46. Kettenmann H (1996) Beyond the neuronal circuitry. Trends Neurosci 19: 305-306.
47. Kilbride J, Huang LQ, Rowan MJ, Anwyl R (1998) Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV. Eur J Pharmacol 356: 149-157.
48. Kingston AE, O'Neill MJ, Lam A, Bales KR, Monn JA, Schoepp DD (1999) Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795. Eur J Pharmacol 377:155-165.
49. Kuiper MA, Teerlink T, Visser JJ, Bergmans PL, Scheltens P, Wolters EC (2000) L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transm 107: 183-189.
50. Laslo P, Lipski J, Funk GD (2001) Differential expression of Group I metabotropic glutamate receptors in motoneurons at low and high risk for degeneration in ALS. Neuroreport 12: 1903-1908.
51. Lee HG, Zhu X, Ghanbari HA, Ogawa O, Raina AK, O'Neill MJ, Perry G, Smith MA (2002a) Differential regulation of glutamate receptors in Alzheimer's disease. Neurosignals 11: 282-292.
52. Lee HG, Ogawa O, Zhu X, O'Neill MJ, Petersen RB, Castellani RJ, Ghanbari H, Perry G, Smith MA (2004) Aberrant expression of metabotropic glutamate receptor2 in the vulnerable neurons in Alzheimer's disease. Acta Neuropathol (Berl), Online First: Feb. 11.
53. Lee RK, Jimenez J, Cox AJ, Wurtman RJ (1996) Metabotropic glutamate receptors regulate APP processing in hippocampal neurons and cortical astrocytes derived from fetal rats. Ann N Y Acad Sci 777: 338-343.
54. Lynch DR, Guttmann RP (2002) Excitotoxicity: perspectives based on N-methyl-D-aspartate receptor subtypes. J Pharmacol Exp Ther 300: 717-723.
55. Matarredona ER, Santiago M, Venero JL, Cano J, Machado A (2001) Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP(+)-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurochem 76: 351-360.
56. Mayer ML, Westbrook GL (1987) The physiology of excitatory amino acids in the vertebrate central nervous system. Prog Neurobiol 28: 197-276.
57. McShea A, Zelasko DA, Gerst JL, Smith MA (1999) Signal transduction abnormalities in Alzheimer's disease: evidence of a pathogenic stimuli. Brain Res 815: 237-242.
58. Meldrum B, Garthwaite J (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11: 379-387.
59. Miller S, Romano C, Cotman CW (1995) Growth factor upregulation of a phosphoinositide-coupled metabotropic glutamate receptor in cortical astrocytes. J Neurosci 15: 6103-6109.
60. Miyamoto M, Ishida M, Shinozaki H (1997) Anticonvulsive and neuroprotective actions of a potent agonist (DCG-IV) for group II metabotropic glutamate receptors against intraventricular kainate in the rat. Neuroscience 77: 131-140.
61. Monaghan DT, Bridges RJ, Cotman CW (1989) The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29: 365-402.
62. Nakazawa K, Quirk MC, Chitwood RA, Watanabe M, Yeckel MF, Sun LD, Kato A, Carr CA, Johnston D, Wilson MA, Tonegawa S (2002) Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science 297: 211-218.
63. Oka A, Takashima S (1999) The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Acta Neuropathol (Berl) 97:275-278.
64. O'Neill MJ (2001) Pharmacology and neuroprotective actions of mGlu receptor ligands. Dev Med Child Neurol Suppl 86: 13-15.
65. Otani S, Auclair N, Desce JM, Roisin MP, Crepel F (1999) Dopamine receptors and groups I and II mGluRs cooperate for long-term depression induction in rat prefrontal cortex through converging postsynaptic activation of MAP kinases. J Neurosci 19: 9788-9802.
66. Page KJ, Everitt BJ, Robbins TW, Marston HM, Wilkinson LS (1991) Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA- and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: differential dependence on cholinergic neuronal loss. Neuroscience 43: 457-472.
67. Panegyres PK, Zafiris-Toufexis K, Kakulas BA (2002) The mRNA of the NR1 subtype of glutamate receptor in Alzheimer's disease. J Neural Transm 109: 77-89.
68. Pearce BR, Bowen DM (1984) [3H]Kainic acid binding and choline acetyltransferase activity in Alzheimer's dementia. Brain Res 310: 376-378.
69. Pechan PA, Chowdhury K, Gerdes W, Seifert W (1993) Glutamate induces the growth factors NGF, bFGF, the receptor FGF-R1 and c-fos mRNA expression in rat astrocyte culture. Neurosci Lett 153: 111-114.
70. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AK, Holbrook N, Siedlak SL, Harris PL, Smith MA (1999) Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 10: 2411-2415.
71. Phillips T, Barnes A, Scott S, Emson P, Rees S (1998) Human metabotropic glutamate receptor 2 couples to the MAP kinase cascade in chinese hamster ovary cells. Neuroreport 9: 2335-2339.
72. Pin JP, Duvoisin R (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34: 1-26.
73. Pin JP, De Colle C, Bessis AS, Acher F (1999) New perspectives for the development of selective metabotropic glutamate receptor ligands. Eur J Pharmacol 375: 277-294.
74. Pizzi M, Consolandi O, Memo M, Spano PF (1996) Activation of multiple metabotropic glutamate receptor subtypes prevents NMDA-induced excitotoxicity in rat hippocampal slices. Eur J Neurosci 8: 1516-1521.
75. Pizzi M, Boroni F, Bianchetti KM, Memo M, Spano P (1999) Reversal of glutamate excitotoxicity by activation of PKC-associated metabotropic glutamate receptors in cerebellar granule cells relies on NR2C subunit expression. Eur J Neurosci 11: 2489-2496.
76. Pogocki D (2003) Alzheimer's β-amyloid peptide as a source of neurotoxic free radicals: the role of structural effects. Acta Neurobiol Exp (Wars) 63: 131-145.
77. Poli A, Beraudi A, Villani L, Storto M, Battaglia G, Di Giorgi Gerevini V, Cappuccio I, Caricasole A, D'Onofrio M, Nicoletti F (2003) Group II metabotropic glutamate receptors regulate the vulnerability to hypoxic brain damage. J Neurosci 23: 6023-6029.
78. Schoepp DD, Jane DE, Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38: 1431-1476.
79. Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M, Flor PJ, Neki A, Abe T, Nakanishi S, Mizuno N (1997) Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 17: 7503-7522.
80. Smith MA (1998) Alzheimer disease. Int Rev Neurobiol 42: 1-54.
81. Smith-Swintosky VL, Pettigrew LC, Craddock SD, Culwell AR, Rydel RE, Mattson MP (1994) Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury. J Neurochem 63: 781-784.
82. Stephenson DT, Clemens JA (1998) Metabotropic glutamate receptor activation in vivo induces intraneuronal amyloid immunoreactivity in guinea pig hippocampus. Neurochem Int 33: 83-93.
83. Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ (2001) N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J Neurol Sci 182: 151-159.
84. Thorns V, Mallory M, Hansen L, Masliah E (1997) Alterations in glutamate receptor 2/3 subunits and amyloid precursor protein expression during the course of Alzheimer's disease and Lewy body variant. Acta Neuropathol (Berl) 94: 539-548.
85. Tomiyama M, Kimura T, Maeda T, Tanaka H, Furusawa K, Kurahashi K, Matsunaga M (2001) Expression of metabotropic glutamate receptor mRNAs in the human spinal cord: implications for selective vulnerability of spinal motor neurons in amyotrophic lateral sclerosis. J Neurol Sci 189: 65-69.
86. Ulas J, Cotman CW (1997) Decreased expression of N-methyl-D-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain. Neuroscience 79: 973-982.
87. Wakabayashi K, Narisawa-Saito M, Iwakura Y, Arai T, Ikeda K, Takahashi H, Nawa H (1999) Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer's disease. Neurobiol Aging 20: 287-295.
88. Weiss JH, Yin HZ, Choi DW (1994) Basal forebrain cholinergic neurons are selectively vulnerable to AMPA/kainate receptor-mediated neurotoxicity. Neuroscience 60: 659-664.
89. Yasuda RP, Ikonomovic MD, Sheffield R, Rubin RT, Wolfe BB, Armstrong DM (1995) Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: a biochemical study. Brain Res 678: 161-167.
90. Ye ZC, Sontheimer H (1999) Metabotropic glutamate receptor agonists reduce glutamate release from cultured astrocytes. Glia 25: 270-281.
91. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA (2000) Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 59: 880-888.
92. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, Smith MA (2001a) Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Ageing Dev 123: 39-46.
93. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA (2001b) Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 76: 435-441.
94. Zhu X, Rottkamp CA, Hartzler A, Sun Z, Takeda A, Boux H, Shimohama S, Perry G, Smith MA (2001c) Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J Neurochem 79: 311-318.